Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Average. Corcept Therapeutics Incorporated scores higher than 38% of the 1,794 companies Ryufin scores.
Carried by return on capital and cycle position, held back by valuation and return on new capital.
Healthcare median 28 · all companies 57
26% of the score
Corcept Therapeutics Incorporated is valued at 1420.5x its operating profit, including debt: past the 60 times where this criterion gives nothing.
18% of the score
Over 7 years the business earned 62% a year after tax on the capital it uses.
16% of the score
Over 6 years yearly profit fell by 5 cents for every dollar earned. New capital earned -13%, and 41% of profit went back into the business.
14% of the score
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
12% of the score
Today's operating margin of 0.8% is 0.03x its normal 28%: near a trough. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
8% of the score
What the debt weighs against the profit that has to carry it.
6% of the score
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.